Wednesday, July 8, 2026

pharma · Acute Myeloid Leukemias · Breast Cancer

Syndax Pharmaceuticals

Syndax Pharmaceuticals is a pharma organization headquartered in New York, USA. Primary therapeutic focus areas include Acute Myeloid Leukemias, Breast Cancer, Acute Myeloid Leukemia, Relapsed or Refractory Acute Leukemi

730 3rd Ave, Floor 9, New York, NY 10017, US HQ
325 Employees
NMPA registrant Type
Company details
Status
Public
HQ
730 3rd Ave, Floor 9, New York, NY 10017, US
Employees
325
Programs
47
Drugs
29
Patents
6
Clinical program

Entinostat

Phase 1 · small molecule · Fallopian Tube Cancer

Entinostat for Fallopian Tube Cancer is a Phase 1 program (small_molecule) at Syndax Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All Syndax Pharmaceuticals projects Phase 1 small molecule terminated

Internal code VICC GYN 1842

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Syndax Pharmaceuticals
Phase
Phase 1
Modality
small_molecule
Indication
Fallopian Tube Cancer
Status
terminated
Trials
1

Clinical trials